Eton Pharma rallies after stronger Q3 results and higher annual outlook
Eton Pharmaceuticals beat Q3 2026 expectations and raised its full-year guidance, according to Seeking Alpha, with premarket shares up over 20%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Eton Pharmaceuticals stock climbed above 20% before the open on Friday after the company posted third-quarter 2026 numbers ahead of forecasts and lifted its yearly targets, Seeking Alpha reported. The Deer Park, Illinois firm focuses on rare-disease medicines.
Revenue reached $57.9 million, up about 158% from a year earlier and $15.7 million above consensus. Management pointed to ongoing volume gains and record active patient numbers for Increlex and Hemangeol. Non-GAAP earnings per share came in at $0.50, versus $0.04 a year ago and $0.13 above estimates.
Adjusted EBITDA rose to $28.5 million from $2.9 million, lifting the margin to 49% from 13%. Gross profit exceeded $44.3 million, more than fivefold higher. The revenue target now stands above $175 million, with an adjusted EBITDA margin of at least 40%, replacing the earlier guidance of over $145 million.
why it matters
For a small drugmaker, a quarter like this is a notable operating signal, though the read-through stays limited to one company. Investors will likely watch whether volume growth and margins hold in coming quarters.
tags
instruments
sources
- Eton Pharma jumps after Q3 beat and guidance hike — Seeking Alpha, 6 November 2026 at 14:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗